A systematic review uncovers apigenin's impact on inflammatory biomarkers in sepsis, suggesting further clinical trials are needed.
Despite its promising effects, further clinical trials are needed to confirm its efficacy and safety in septic patients.
No takes yet. Share an insight, caveat, or question.
Oriquat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: